Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Kedudukan dalam Saham #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Harga Saham
$17.82
Disegerakkan terakhir: 2026-09-11
Modal Pasaran
$32.43B
Perubahan (1 hari)
0.83%
Perubahan (1 tahun)
-25.31%
Negara
JP
Perdagangan Daiichi Sankyo Company, Limited (4568)

Kategori

Nisbah P/E bagi Daiichi Sankyo Company, Limited (4568)
Nisbah P/E pada September 2026 TTM: 21.74
Menurut laporan kewangan dan harga saham terkini Daiichi Sankyo Company, Limited, nisbah P/E semasa (TTM) ialah 21.74. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 44.58.
Sejarah nisbah P/E bagi Daiichi Sankyo Company, Limited dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 21.74 -3.43%
2025 22.51 -49.50%
2024 44.58 -47.34%
2023 84.66 10.38%
2022 76.70 -6.85%
2021 82.34 120.64%
2020 37.32 -2.53%
2019 38.29 -0.84%
2018 38.61 22.65%
2017 31.48 50.17%
2016 20.96 403.01%
2015 4.17 -79.24%
2014 20.08 9.51%
2013 18.33 -82.07%
2012 102.24 534.14%
2011 16.12 -45.26%
2010 29.45 -643.67%
2009 -5.42 -124.90%
2008 21.76 -35.05%
2007 33.50 49.10%
2006 22.47 0.07%
2005 22.45 9.57%
2004 20.49 -2.12%
2003 20.94 -26.72%
2002 28.57 -7.80%
2001 30.99 81.88%
2000 17.04 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
38.79 78.44%
US
30.73 41.39%
US
72.23 232.29%
US
22.25 2.35%
CH
117.27 439.49%
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.